Latest Conference Articles

Trabeculectomy may offer better results with more severe glaucoma

ASRS 2020: Josh Anderson speaks on the highlights from Alcon, including new data on the performance benefits of the Hypervit dual blade 20,000 cpm probe and the launch of the NGENUITY 1.4 upgrade.

PDS with ranibizumab is proving to be an innovation solution for nAMD patients. Peter Campochiaro, MD, detailed findings of phase 2 of the Ladder Trial and ongoing Archway Trial during the virtual 2020 ASRS annual meeting.

The results of the Protocol T Extension Study underscore the need for methods to improve long-term visual gains in eyes with diabetic macular edema, according to Dante Pieramici, MD, on behalf of the DRCR Retina Network, during the American Society of Retina Specialists 2020 Virtual Annual Meeting.

Carl Danzig, MD, presented results of phase 2 Stairway Trial during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

ASRS 2020 coverage: Carl Danzig, MD, presented results of phase 2 Stairway Trial during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting. Faricimab is a bispecific antibody that simultaneously inhibits angiopoietin-2 and vascular endothelial growth factor A.

Technology is off to a good start, but improvements still needed

ASRS 2020 coverage: An augmented-reality device provides AMD patients with enhanced reading ability and facial recognition.

An augmented-reality device provides AMD patients with enhanced reading ability and facial recognition.

The Audacious Goals Initiative of the National Eye Institute is focused on developing noninvasive imaging advances to help patients with vision loss.

ASRS 2020 coverage: Intravitreal liposome-encapsulated bromfenac is under study as a treatment for refractory DME. Results of a pilot study were detailed at the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

ASRS 2020 coverage: The Audacious Goals Initiative of the National Eye Institute is focused on developing noninvasive imaging advances to help patients with vision loss.

Diagnostic and monitoring advances in glaucoma need fine-tuning

With an eye on innovation, money is driving research of new therapies and devices.

Industry develops creative approaches to help increase patient medication adherence

Panel discusses IOP monitoring, drug delivery, data collection

ICYMI: Nir Israeli, co-founder and CEO of Sanoculis discusses the company's new alternative surgical procedure for glaucoma designed to create a single-patient-use sterile tool and a multi-use external machine.

For many physicians, “moral injury” may be actual issue

ICYMI: Chris Adams, CEO of Diopter Corp, discusses the company's drug delivery contact lens technology in the pipeline that works to treat ocular surface disease, during the 2020 Glaucoma 360 meeting in San Francisco, California.

ICYMI: Ramin Valian, vice president of International Glaucoma, Reimbursement and Pipeline at Allergan, discusses glaucoma from a therapeutics/diagnostics and big data sets standpoint during the 2020 Glaucoma 360 meeting.

High-level observations for how the latest developments can help glaucoma specialists solve problems to achieve the utmost in patient care

Besides traditional medications, here are some of the many novel approaches to treat patients with glaucoma

The American Academy of Ophthalmology (AAO) is taking its annual meeting virtual amid the COVID-19 pandemic.

There are other mimickers of NTG that should be kept in mind

New products increase the chance of early diagnosis

ICYMI: Daria Lemann Blumenthal, CEO of BELKIN Laser, Ltd., discusses the company's current initiative of developing an automated one-second laser therapy for glaucoma called direct selective laser trabeculoplasty (DSLT).

New therapies on the horizon offer options for slowing progression

ICYMI: Yvonne Ou, MD, discusses her presentation on "Apps for the visually challenged," during the 2020 Glaucoma 360 annual meeting in San Francisco, California.